Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year. The post Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer appeared first on MedCity News.

BMS' radiopharma unit builds with $1.35bn Philochem deal

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.

BMS’ RayzeBio inks radiopharma deal in prostate cancer for $350M upfront

Bristol Myers Squibb’s subsidiary RayzeBio is spending $350 million upfront to license an early-stage radiopharmaceutical candidate for prostate cancer from Philochem. RayzeBio will get global rights to a preclinical actinium-based asset, called OncoACP3, which is ...